scholarly journals A TTP-incorporated scoring model for predicting mortality of solid tumor patients with bloodstream infection caused by Escherichia coli

2021 ◽  
Author(s):  
Qing Zhang ◽  
Hao-Yang Gao ◽  
Ding Li ◽  
Chang-Sen Bai ◽  
Zheng Li ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
High Risk ◽  
Bloodstream Infection ◽  
Solid Tumor ◽  
Prognostic Scores ◽  
Risk Scores ◽  
Youden Index ◽  
Tumor Patients ◽  
Scoring Model ◽  
Significant Difference

Abstract Background Few mortality-scoring models are available for solid tumor patients who are predisposed to develop Escherichia coli–caused bloodstream infection (ECBSI). We aimed to develop a mortality-scoring model by using information from blood culture time to positivity (TTP) and other clinical variables. Methods A cohort of solid tumor patients who were admitted to hospital with ECBSI and received empirical antimicrobial therapy was enrolled. Survivors and non-survivors were compared to identify the risk factors of in-hospital mortality. Univariable and multivariable regression analyses were adopted to identify the mortality-associated predictors. Risk scores were assigned by weighting the regression coefficients with corresponding natural logarithm of the odds ratio for each predictor. Results Solid tumor patients with ECBSI were distributed in the development and validation groups, respectively. Six mortality-associated predictors were identified and included in the scoring model: acute respiratory distress (ARDS), TTP ≤ 8 h, inappropriate antibiotic therapy, blood transfusion, fever ≥ 39 °C, and metastasis. Prognostic scores were categorized into three groups that predicted mortality: low risk (< 10% mortality, 0–1 points), medium risk (10–20% mortality, 2 points), and high risk (> 20% mortality, ≥ 3 points). The TTP-incorporated scoring model showed excellent discrimination and calibration for both groups, with AUC being 0.833 vs 0.844, respectively, and no significant difference in the Hosmer–Lemeshow test (6.709, P = 0.48) and the chi-square test (6.993, P = 0.46). Youden index showed the best cutoff value of ≥ 3 with 76.11% sensitivity and 79.29% specificity. TTP-incorporated scoring model had higher AUC than no TTP-incorporated model (0.837 vs 0.817, P < 0.01). Conclusions Our TTP-incorporated scoring model was associated with improving capability in predicting ECBSI-related mortality. It can be a practical tool for clinicians to identify and manage bacteremic solid tumor patients with high risk of mortality.

scholarly journals Development of a Mortality Prediction Model Combined With time to Positivity for Solid Tumor Patients with Escherichia Coli Bacteremia

2020 ◽  
Author(s):  
Qing Zhang ◽  
Haoyang Gao ◽  
Ding Li ◽  
Changsen Bai ◽  
Zheng Li ◽  
...  
Keyword(s):  
Risk Factors ◽  
Escherichia Coli ◽  
Logistic Regression ◽  
Cancer Patients ◽  
Tumor Patients ◽  
Scoring Model ◽  
Time To Positivity ◽  
Significant Difference ◽  
Development And Validation ◽  
Risk Of Cancer

Abstract Background: To develop a scoring model incorporating time to positivity (TTP) into clinical variables for predicting the mortality of tumor patients with Escherichia coli caused bloodstream infection (ECBSI).Methods: A retrospective single center study enrolling hospitalized cancer patients with ECBSI was conducted from 2013 to 2018. The patients were randomly divided into development and validation groups. Univariable and multivariable logistic regression analysis were used to identify risk factors for mortality. The scoring model was developed and validated based on logistic regression coefficients.Results: 315 and 194 patients with ECBSI were included in development and validation groups, respectively. Six significant risk factors for mortality were identified and included in the scoring model: fever ≥ 39℃, inappropriate antibiotic therapy, metastasis, acute respiratory distress (ARDS), blood transfusion, and TTP ≤ 8h. Patients were classified into low-risk (<10% mortality), medium-risk (10%-20% mortality) and high-risk (≥20% mortality) categories based on the predicted mortality rates in each score. The predicted mortality for the three categories was 4.38%, 15.39%, and 51.77%, respectively, in the development group, and 3.72%, 13.88%, and 50.09%, respectively, in the validation group. The model showed excellent discrimination and calibration for both groups, with AUC curves being 0.858 versus 0.835, respectively, and no significant difference in the Hosmer-Lemeshow test (6.709, P=0.48) and the Chi-square test (6.993, P=0.46). Sensitivity and negative predictive values (NPV) increased along with the decrease of cut-off values.Conclusion: The developed TTP-combined scoring model is feasible for clinicians to predict the mortality risk of cancer patients with ECBSI.

Species distribution and antimicrobial susceptibility profile of gram-negative bacteria in hospitalized cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e20730-e20730
Author(s):  
H. M. Ashour ◽  
A. El-Sharif
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Cancer Patients ◽  
Solid Tumor ◽  
Klebsiella Pneumonia ◽  
Gram Negative Bacteria ◽  
Isolation And Identification ◽  
Tumor Patients ◽  
Acinetobacter Species ◽  
Gram Negative

e20730 Background: Nosocomial infections pose significant threats to hospitalized patients, especially the immunocompromised ones, such as cancer patients. Methods: This study examined the microbial spectrum of gram-negative bacteria in various infection sites in patients with leukemia and solid tumors. The antimicrobial resistance patterns of the isolated bacteria were studied. Results: The most frequently isolated gram-negative bacteria were Klebsiella pneumonia (31.2%) followed by Escherichia coli (22.2%). We report the first-time isolation and identification of a number of less-frequent gram negative bacteria (Chromobacterium violacum, Burkholderia cepacia, Kluyvera ascorbata, Stenotrophomonas maltophilia, Yersinia pseudotuberculosis, and Salmonella arizona). Most of the gram-negative isolates from RTI, GITI, UTI, and BSI were obtained from leukemic patients. All gram-negative isolates from SI were obtained from solid-tumor patients. In both leukemic and solid-tumor patients, gram-negative bacteria causing UTI were mainly Escherichia coli and Klebsiella pneumoniae, while gram-negative bacteria causing RTI were mainly Klebsiella pneumoniae. Escherichia coli was the main gram-negative pathogen causing BSI in solid-tumor patients and GITI in leukemic patients. Isolates of Escherichia coli, Klebsiella, Enterobacter, Pseudomonas, and Acinetobacter species were resistant to most antibiotics tested. There was significant imipenem-resistance in Acinetobacter (40.9%), Pseudomonas (40%), and Enterobacter (22.2%) species, and noticeable imipinem-resistance in Klebsiella (13.9%) and Escherichia coli (8%). Conclusions: This is the first study to report the evolution of imipenem-resistant gram-negative strains in Egypt. Mortality rates were higher in cancer patients with nosocomial Pseudomonas infections than any other bacterial infections. Policies restricting antibiotic consumption should be implemented to avoid the evolution of newer generations of antibiotic resistant-pathogens. No significant financial relationships to disclose.

scholarly journals Identification of N6-Methyladenosine-Associated Long Non-coding RNAs for Immunotherapeutic Response and Prognosis in Patients With Pancreatic Cancer

2021 ◽  
Vol 9 ◽  
Author(s):  
Xinshuang Yu ◽  
Peng Dong ◽  
Yu Yan ◽  
Fengjun Liu ◽  
Hui Wang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
T Cell ◽  
High Risk ◽  
Messenger Rna ◽  
Risk Group ◽  
High Risk Group ◽  
Low Risk ◽  
Risk Scores ◽  
Significant Difference ◽  
Selection Operator

Pancreatic cancer is a highly aggressive disease with poor prognosis. N6-methyladenosine (m6A) is critical for post-transcriptional modification of messenger RNA (mRNA) and long non-coding RNA (lncRNA). However, the m6A-associated lncRNAs (m6A-lncRNA) and their values in predicting clinical outcomes and immune microenvironmental status in pancreatic cancer patients remain largely unexplored. This study aimed to evaluate the importance of m6A-lncRNA and established a m6A-lncRNA signature for predicting immunotherapeutic response and prognosis of pancreatic cancer. The m6A-lncRNA co-expression networks were constructed using data from the TCGA and GTEx database. Based on the least absolute shrinkage and selection operator (LASSO) analysis, we constructed an 8 m6A-lncRNA signature risk model, and selection operator (LASSO) analysis, and stratified patients into the high- and low-risk groups with significant difference in overall survival (OS) (HR = 2.68, 95% CI = 1.74–4.14, P &lt; 0.0001). Patients in the high-risk group showed significantly reduced OS compared to patients in the low-risk group (P &lt; 0.001). The clinical characteristics and m6A-lncRNA risk scores were used to construct a nomogram which accurately predicted the OS in pancreatic cancer. TIMER 2.0 were used to investigate tumor immune infiltrating cells and its relationship with pancreatic cancer. CIBERSORT analysis revealed increased higher infiltration proportions of M0 and M2 macrophages, and lower infiltration of naive B cell, CD8+ T cell and Treg cells in the high-risk group. Compared to the low-risk group, functional annotation using ssGSEA showed that T cell infiltration and the differential immune-related check-point genes are expressed at low level in the high-risk group (P &lt; 0.05). In summary, our study constructed a novel m6A-associated lncRNAs signature to predict immunotherapeutic responses and provided a novel nomogram for the prognosis prediction of pancreatic cancer.

Interaction between route of intra-CSF chemotherapy administration and efficacy of therapy in patients wtih neoplastic meningitis

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 1530-1530 ◽  
Author(s):  
M. J. Glantz ◽  
M. C. Chamberlain ◽  
T. Batchelor ◽  
W. Eric ◽  
F. Cavalli ◽  
...  
Keyword(s):  
Sustained Release ◽  
Solid Tumor ◽  
Progression Free Survival ◽  
Intraventricular Administration ◽  
Tumor Patients ◽  
Acute Leukemias ◽  
Free Survival ◽  
Chemotherapy Administration ◽  
Significant Difference ◽  
And Control

1530 Background: NM is a devastating complication of solid tumor and hematologic malignancies. Although controversial, the current standard of care for patients with this disease includes intra-CSF chemotherapy. The importance of route of chemotherapy administration, however, remains controversial. Methods: 124 patients with NM from solid tumors (100 patients) or lymphoma (24 patients) were randomized to receive either sustained-release cytarabine—the study arm; or conventional intra-CSF chemotherapy (methotrexate for solid tumor patients; non-sustained-release cytarabine for lymphoma patients)—the control arm. The route of administration (lumbar vs. ventricular) was not specified. Results: Patients in the study and control arms were well-balanced for factors of known prognostic importance, including age, KPS, and extent of systemic tumor. Progression-free survival was identical between the study and control treatment arms for all patients (35 vs. 43 days, p = 0.73), for solid tumor patients alone (35 vs. 37.5 days, p = 0.79), and for lymphoma patients alone (34 vs. 50 days, p = 0.82). When outcome was examined in solid tumor patients as a function of route of chemotherapy administration, there was no difference in progression-free survival for patients treated with DepoCyt by the ventricular vs. lumbar routes (29 vs. 43 days, p = 0.35). For patients treated with methotrexate, there was a statistically significant difference favoring patients receiving intraventricular therapy (43 vs. 19 days, p = 0.048). Conclusions: Both the pharmacokinetic profile of the intra-CSF chemotherapeutic agent and the site of administration influence the outcome of patients treated for NM. Intraventricular administration, or the use of sustained-release chemotherapeutic agents if the lumbar route is used, appears to be critical to the success of treatment. The implications of this finding may also extend to patients (e.g. those with acute leukemias, high-risk NHL, or her2/neu-positive breast cancer) receiving prophylactic intra-CSF chemotherapy since, in the prophylactic setting, intra-lumbar chemotherapy administration is almost always employed. [Table: see text]

Role of the oncological-multidimensional prognostic index in older patients with metastatic colorectal cancer treated in a real-world setting.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 11552-11552
Author(s):  
Letizia Procaccio ◽  
Antonella Brunello ◽  
Pasquale Fiduccia ◽  
Annunziata Lettiero ◽  
Giuseppina Tierno ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
High Risk ◽  
Geriatric Assessment ◽  
Real World ◽  
Prognostic Index ◽  
Risk Scores ◽  
Real World Setting ◽  
Significant Difference ◽  
Ecog Ps

11552 Background: About 50% of diagnoses of colorectal cancer (CRC) occur in patients (pts) older than 70 years. Though a comprehensive geriatric assessment (CGA) is recommended for proper management of older cancer pts, there is still no consensus on the best form of geriatric assessment. We investigated possible prognostic factors in elderly metastatic (m)CRC pts in a real-world setting, focusing on the role of the oncological-multidimensional prognostic index (onco-MPI). Methods: Pts aged ≥ 70 years with mCRC referred to the Medical Oncology 1 Unit from May 2010 to May 2017 were assessed by a multidisciplinary team and received a basal CGA. Onco-MPI was calculated by a validated algorithm as a weighted linear combination of the CGA domains, as previously described. The following 3 different prognostic groups were identified: low (scores 0.0-0.46), medium (scores 0.47-0.63) and high risk (scores 0.64-1.0). Results: A total of 206 mCRC pts were included, 123 males. Mean age was 76.1 years (69.2-90.8). ECOG PS was < 2 in 90% and mini-mental state examination was ≥ 24 in 85% of pts. Primary tumor was located in rectum, left and right side in 18%, 42% and 40% of pts, respectively. RAS and BRAF mutations were detected in 44% and 9% of pts, respectively. According to onco-MPI score, 32%, 39% and 28% of cases were low, medium and high risk, respectively. According to CGA as per Balducci’s criteria, 56% of pts were classified as fit, 31% vulnerable and 13% frail. Median overall survival (OS) was 26 months (95% CI 19.7-32.4). The following factors were significantly associated with OS: ECOG PS (0-1 vs > 1, 31% vs 15%, p = 0.004); onco-MPI score (low vs medium vs high risk, 29% vs 38% vs 19%, p = 0.005), treatment (monotherapy vs doublet vs triplet, 20% vs 31% vs 30%, p = 0.01). No significant difference in OS was observed in CGA-based groups (p = 0.15). In high onco-MPI score, doublet-regimen correlated with higher OS compared to monotherapy (79% vs 51%, p = 0,03). Conclusions: Onco-MPI emerged as a significant prognosticator in mCRC elderly pts. It may be useful in daily clinical practice for driving decision-making in this age group. Thanks to its marked standardization it may be also applied in clinical trials.

A Randomized Control Trial of a Targeted High-Risk Offender Program Across Three Jurisdictions

2018 ◽  
Vol 22 (2) ◽  
pp. 192-216 ◽  
Author(s):  
Craig D. Uchida ◽  
Marc Swatt ◽  
Julie Schnobrich-Davis ◽  
Christine Connor ◽  
Mariel Shutinya ◽  
...  
Keyword(s):  
High Risk ◽  
Risk Scores ◽  
Future Research ◽  
Records Management ◽  
Individual Level ◽  
Focused Deterrence ◽  
Significant Difference ◽  
One Year ◽  
And Control ◽  
The Impact

This study reviews findings from Project Regional Analytics for the Safety of Our Residents, a modified focused deterrence program operated across three jurisdictions in Massachusetts. Unlike most other evaluations of targeted high-risk offender programs, the impact on individual-level offending is examined. Data from records management systems in three police agencies were extracted and used to create social harm risk scores. The top 150 offenders were selected for inclusion in this study. Subjects were blocked into three groups according to their composite score and then randomly assigned into treatment and control groups. All treatment group offenders were invited to a notification meeting where they decided whether to participate in the program with a police and social worker case management team. The outcome examined in this study is time to a new arraignment. Nonparametric and semiparametric methods detected no significant difference between groups after approximately one year. Implications for future research and practice are then discussed.

scholarly journals The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors

2021 ◽  
Author(s):  
Hana Kim ◽  
Soomin Ahn ◽  
Hongsik Kim ◽  
Jung Yong Hong ◽  
Jeeyun Lee ◽  
...  
Keyword(s):  
Homologous Recombination ◽  
Solid Tumor ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Rare Cancer ◽  
Tumor Patients ◽  
Homologous Recombination Deficiency ◽  
Significant Difference ◽  
The Status

Abstract Purpose Homologous recombination deficiency (HRD) is related to tumorigenesis. Currently, the possibility of HRD as a prognostic biomarker to immune checkpoint inhibitors is unknown. We aimed to investigate whether HRD has potential as a biomarker for immunotherapy. Methods The status of homologous recombination deficiency (HRD) was assessed with the next-generation sequencing (NGS) TruSight™ Oncology 500 assay in 501 patients with advanced solid tumor including gastrointestinal (GI), genitourinary (GU), or rare cancer. Results: among the 501 patients, HRD was observed as follows: 74.7% (347/501) patients; GU cancer (92.0%, 23 of 25), colorectal cancer (CRC) (86.1%, 130 of 151), hepatocellular carcinoma (HCC) (83.3%, 10 of 12), pancreatic cancer (PC) (76.2%, 32 of 42), biliary tract cancer (BTC) (75.0%, 36 of 48), sarcoma (65.0%, 39 of 60), melanoma (52.4%, 11 of 21), other GI cancers (50.0%, 11 of 22), and rare cancer (50.0%, 2 of 4). Sixty-five of the 501 patients had received immune checkpoint inhibitors (ICIs) during the course of the disease. Tumor types of 65 patients treated with ICIs are as follows: melanoma (95.2%, 20 of 21), HCC (33.3%, 4 of 12), rare cancer (25.0%, 1 of 4), GC (12.2%, 14 of 116), BTC (10.4%, 5 of 48), and sarcoma (5.0%, 3 of 60). The most frequently reported mutations were BRCA2 (n = 90), ARID1A (n = 77), ATM (n = 71), BARD1 (n = 67). Patients without HRD exhibited an objective response rate (ORR) of 33.3% (4 of 12), and patients with HRD exhibited an ORR of 34.0% (18 of 53). There was no significant difference in ORR between patients with and without HRD (P = 0.967). Progression-free survival (PFS) was 6.5 months (95% CI 0.000–16.175) in patients without HRD and 4.1 months (95% CI 2.062–6.138) in patients with HRD, revealing no statistical significance (P = 0.441). Conclusion Herein, we reported the status of HRD using a cancer-panel for various solid tumor patients in routine clinical practice and demonstrated that HRD as a single biomarker was not sufficient to predict efficacy of ICIs in solid tumor patients.

scholarly journals FRI0499 ACROMEGALY ARTROPATHY: IS THERE SOMETHING MORE BEHIND THE PAIN? A CROSS-SECTIONAL STUDY TO EVALUATE RHEUMATIC DISEASE IN GROWTH HORMONE SECRETING TUMOR PATIENTS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 848.1-848
Author(s):  
M. Scarati ◽  
S. Parisi ◽  
N. Prencipe ◽  
M. C. Ditto ◽  
E. Ghigo ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Logistic Regression ◽  
Rheumatic Disease ◽  
Power Doppler ◽  
Connective Tissue Diseases ◽  
Joint Damage ◽  
Joint Space ◽  
Tumor Patients ◽  
Cross Sectional ◽  
Significant Difference

Background:Acromegaly is a rare disease with a remarkable impact on patients, both in terms of life expectancy and quality of life. Osteo-articular complications are one of the most frequently reported bothers. The “acromegaly artropathy” characterizes more than 70% of patients at diagnosis. Artropathy affects both spine and peripheral joints. A recent prospective study documented progression of acromegalic arthropathy identified as a worsening of osteophytes and joint space narrowing in 72–74% of patients despite long-term biochemical control. In addiction the Literature has occasionally reported cases of simultaneous presence of rheumatic diseases (rheumatoid arthritis, polymyalgia rheumatica, undifferentiated connective tissue diseases) and acromegaly and in all these cases the treatment has been delayed, because of wrong symptoms attribution to acromegaly artropathy.Objectives:The primary goal of the study is to better characterize joint pain in acromegaly patients and to evaluate the prevalence of rheumatic disease in growth hormone (GH) secreting pituitary tumor patients.Methods:We enrolled 20 acromegaly subjects (AS) and 20 control subjects (CS). In each subject immunological pattern (rheumatoid factor – RF; antinuclear antibodies - ANA, ENA; anti-citrullinated protein antibodies - ACPA; erythrocyte sedimentation rate – ESR) has been evaluated; they, also, underwent bilateral joint ultrasound of hands and wrists and nail capillaroscopy. The Chi square test and the Fisher’s exact test were used to evaluate the association between binary variables, while the Spearman’s test to evaluate the correlation of continuous ones. A multiple or logistic regression model was calculated in order to define the association between the capillaroscopic alterations and other detected variables.Results:Articular pain emerged as significantly more frequent in AS (p = 0.0269). No statistically significant differences are detected regarding immunological pattern. ANA and ENA screening resulted positive in 10% in AS and in 5% in CS. No IgA ACPA were detected in AS or CS, while IgG ACPA were positive only in one AS subject. No significant differences were detected between IgM and IgG RFin the two groups (AS 5% and CS 0%). Three fold higher IgG FR in AS compared to CS were detected. ESR levels were significantly higher than CS (p = 0.0405), as well as increased power doppler (PWD) articular uptake (AS 30% vs CS 5% p 0.081). The capillaroscopic evaluation showed a significant difference in almost each parameter that has been evaluated (logistic regression: number of enlargement p 0.004, hemorragies p 0.01 and capillaries p 0.001), showing a moderate-severe microangiopathy in AS. Interestingly, analyzing only the acromegaly cohort, we noticed higher GH levels at the enrollment in patients which developed capillary enlargements (GH: 0.95 ng/ml IQ 0,6-1,6) compared to other ones (GH: 0.55 ng/ml IQ 0.4-0.7; p = 0.08) and a significant lower number of hemorrhages (p = 0.02) in patients treated with GH antagonist pegvisomant.Conclusion:Our results demonstrated that joint damage in acromegaly does not seem to have an autoimmune etiology. Therefore, articular damage is mechanical and increased ESR and PWD alterations seems to confirm the presence of an inflammatory component. In addition, acromegaly is characterized by a microvascular pattern of moderate-severe microangiopathy, without correlation to IGF-I, but GH levels. Although requiring further confirmatory studies, our preliminary results seem to indicate how the capillaroscopic examination could be useful to detect earlier microangiopathy and to identify patients with a greater risk of macroangiopathy development..References:[1]Claessen KMJA et al. Bone and joint disorders in acromegaly. Neuroendocrinology. 2016;103(1):86-95.[2]Örük G et al. Is every joint symptom related to acromegaly? Endocrine. 2013 Apr;43(2):404-11.Disclosure of Interests:None declared

scholarly journals Neurodevelopmental Outcomes at 18 Months of Corrected Age for Late Preterm Infants Born at 34 and 35 Gestational Weeks

2021 ◽  
Vol 18 (2) ◽  
pp. 640 ◽  
Author(s):  
Ruka Nakasone ◽  
Kazumichi Fujioka ◽  
Yuki Kyono ◽  
Asumi Yoshida ◽  
Takumi Kido ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Late Preterm ◽  
Psychomotor Development ◽  
Youden Index ◽  
Chromosomal Anomalies ◽  
Clinical Factors ◽  
Neurodevelopmental Outcomes ◽  
Late Preterm Infants ◽  
Significant Difference ◽  
Severe Hyperbilirubinemia

To date, the difference in neurodevelopmental outcomes between late preterm infants (LPI) born at 34 and 35 gestational weeks (LPI-34 and LPI-35, respectively) has not been elucidated. This retrospective study aimed to evaluate neurodevelopmental outcomes at 18 months of corrected age for LPI-34 and LPI-35, and to elucidate factors predicting neurodevelopmental impairment (NDI). Records of all LPI-34 (n = 93) and LPI-35 (n = 121) admitted to our facility from 2013 to 2017 were reviewed. Patients with congenital or chromosomal anomalies, severe neonatal asphyxia, and without developmental quotient (DQ) data were excluded. Psychomotor development was assessed as a DQ using the Kyoto Scale of Psychological Development at 18 months of corrected age. NDI was defined as DQ < 80 or when severe neurodevelopmental problems made neurodevelopmental assessment impossible. We compared the clinical characteristics and DQ values between LPI-34 (n = 62) and LPI-35 (n = 73). To elucidate the factors predicting NDI at 18 months of corrected age, we compared clinical factors between the NDI (n = 17) and non-NDI (n = 118) groups. No significant difference was observed in DQ values at 18 months of corrected age between the groups in each area and overall. Among clinical factors, male sex, intraventricular hemorrhage (IVH), hyperbilirubinemia, and severe hyperbilirubinemia had a higher prevalence in the NDI group than in the non-NDI group, and IVH and/or severe hyperbilirubinemia showed the highest Youden Index values for predicting NDI. Based on the results of this study, we can conclude that no significant difference in neurodevelopmental outcomes at 18 months of corrected age was observed between LPI-34 and LPI-35. Patients with severe hyperbilirubinemia and/or IVH should be considered to be at high risk for developing NDI.

Sign in / Sign up

Export Citation Format

Share Document